Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive
Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.
29/435
Coincidencias para
“Dyslipidemia”
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
…treatment to improve the severe dyslipidemia. However, late-onset LALD should be…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
…The percent of patients with overweight, obesity, diabetes, hypertension, and dyslipidemia were…
-
The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
…factors such as diabetes mellitus, dyslipidemia, and obesity. The MCV value and…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
**Background/Objectives**: Prior research has identified a significant association between heart disease…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
### Objective Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.